Cocaine abuse and dependence: Approaches to management

CNS Drugs

Volumn 10, Issue 1, 1998, Pages 43-59

  Nathan, Kalpana I ^a   Bresnick, William H ^a   Batki, Steven L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; BUPRENORPHINE; CARBAMAZEPINE; CENTRAL STIMULANT AGENT; COCAINE; DESIPRAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; IMIPRAMINE; LEVODOPA; LITHIUM; LORAZEPAM; MAZINDOL; METHADONE; METHYLPHENIDATE; NICOTINE; NIFEDIPINE; PHENYTOIN; PLACEBO;

ANXIETY NEUROSIS; CLINICAL PROTOCOL; CLINICAL TRIAL; DEMOGRAPHY; DRUG ABUSE; DRUG ABUSE PATTERN; DRUG DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METHADONE TREATMENT; MOOD; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOSOCIAL CARE; REVIEW; VIRUS TRANSMISSION; WITHDRAWAL SYNDROME;

EID: 0031815921     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199810010-00004     Document Type: Review

References (97)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994
2. Goldstein A. The wild addictions: cocaine and amphetamines. In: Addiction: from biology to drug policy. New York (NY): W.H. Freeman and Company, 1994: 155-67
3. Benowitz N. Clinical pharmacology and toxicology of cocaine. Pharmacol Toxicol 1993; 72: 3-12
4. Jones RT. The pharmacology of cocaine. In Grabowski J, editor. Cocaine: pharmacology effects, and treatment of abuse. NIDA Res Monogr 1984; 50: 34-53
5. Gold MS. The neurobiology of addictive disorders: the role of dopamine, endorphin and serotonin. In: Miller NS, editor. The principles and practice of addictions in psychiatry. Philadelphia: W.B. Saunders Company, 1997: 57-69
6. Gawin FH, Kleber HD. Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Arch Gen Psychiatry 1986; 43: 107-13
7. Lago JA, Kosten TR. Stimulant withdawal. Addiction 1994; 89 (11): 1477-81
8. Gawin FH. Cocaine addiction: psychology and neurophysiology. Science 1991; 251: 1580-6
9. Preliminary estimates from the 1995 National Household Survey on Drug Abuse (NHSDA). http://www.health.org/pubs/ 95hhs/ar18txt.htm
10. Preliminary estimates from the Drug Abuse Warning Network (DAWN): 1996 DAWN survey. http://www.health.org/pubs/ 96dawn/ar17.htm
11. Larrat EP, Ziegler S. Entangled epidemics: cocaine use and HIV disease. J Psychoactive Drugs 1993; 25 (3): 207-21
12. Goldstein PJ, Oullet LJ, Fendrich M. From bags brides to skeezers: a historical perspective on sex-for-drugs behavior. J Psychoactive Drugs 1992; 24 (4): 349-61
13. Haim DY, Lippmann ML, Goldberg SK, et al. The pulmonary complications of crack cocaine: a comprehensive review. Chest 1995; 107: 233-40
14. O'Connor PG, Chang G, Shi J. Medical complications of cocaine use. In: Kosten TR, Kleber HD, editors. Clinician's guide to cocaine addiction: theory, research and treatment. New York/London: The Guilford Press, 1992: 241-72
15. Fox CH. Cocaine use in pregnancy. J Am Board Fam Pract 1994; 7: 225-8
16. Halikas JA, Crosby RD, Pearson VL, et al. Psychiatric comorbidity in treatment-seeking cocaine abusers. Am J Addict 1994; 3 (1): 25-35
17. Ziedonis DM, Rayford BS, Bryant KJ, et al. Psychiatric comorbidity in whites and African-American cocaine addicts seeking substance abuse treatment. Hosp Community Psychiatry 1994; 45 (1): 43-9
18. Kleinman PA, Miller AB, Millman RB, et al. Psychopathology among cocaine abusers entering treatment. J Nerv Ment Dis 1990; 178 (7): 442-7
19. Des Jarlais DC. Harm reduction: a framework for incorporating science in drug policy. Am J Pub Health 1995; 85 (1): 10-2
20. American Psychiatric Association. Practice guidelines for the treatment of patients with substance use disorders: alcohol, cocaine, opioids. Am J Psychiatry 1995; 152 (11 Suppl.): 1-59
21. Budde D, Rounsaville B, Bryant K. Inpatient and outpatient cocaine abusers: clinical comparisons at intake and one-year follow-up. J Subst Abuse Treat 1992; 9 (4): 337-42
22. Alterman AI, O'Brien CP, McLellan AT, et al. Effectiveness and costs of inpatient versus day hospital cocaine rehabilitation. J Nerv Ment Dis 1994; 182 (3): 157-63.
23. United States General Accounting Office. Cocaine treatment: early results from various approaches. Washington, DC: US Government Printing Office, 1996 Jun: 1-34
24. Schuckit MA. Drug and alcohol abuse: a clinical guide to diagnosis and treatment. 4th ed. New York (NY): Plenum, 1995: 328-30
25. Carroll KM, Rounsaville BJ, Keller DS. Relapse prevention strategies for the treatment of cocaine abuse. Am J Drug Alcohol Abuse 1991; 17 (3): 249-65
26. Carroll KM, Rounsaville BJ, Gawin FH. A comparative trial of psychotherapies for ambulatory cocaine abusers: relapse prevention and interpersonal psychotherapy. Am J Drug Alcohol Abuse 1991; 17 (3): 229-47
27. Carroll KM, Rounsaville BJ, Gordon LT, et al. Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Arch Gen Psychiatry 1994; 51: 177-87
28. Wallace BC. Treating crack cocaine dependence: the critical role of relapse prevention. J Psychoactive Drugs 1992; 24(2): 213-22
29. Higgins ST, Budney AJ. Treatment of cocaine dependence through the principles of behavior analysis and behavioral pharmacology. In: Onken LS, Blaine JD, Boren JJ, editors. Behavioral treatments for drug abuse and dependence. NIDA Res Monogr 1993; 139: 97-121
30. Higgins ST, Budney AJ, Bickel WK, et al. Achieving cocaine abstinence with a behavioral approach. Am J Psychiatry 1993; 150 (5): 763-8
31. Higgins ST, Budney AJ, Bickel WK, et al. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch Gen Psychiatry 1994; 51: 568-76
32. Silverman K, Higgins ST, Brooner RK, et al. Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. Arch Gen Psychiatry 1996; 53: 409-15
33. Rawson RA, Obert JL, McCann MJ, et al. Psychological approaches for the treatment of cocaine dependence: a neurobehavioral approach. J Addictive Dis 1991; 11 (2): 97-119
34. Shoptaw S, Rawson RA, McCann MJ, et al. The matrix model of outpatient stimulant abuse treatment: evidence of efficacy. J Addict Dis 1994; 13 (4): 129-41
35. Hoffman JA, Caudill BD, Koman JJ, et al. Psychosocial treatments for cocaine abuse: 12-month treatment outcomes. J Subst Abuse Treat 1996; 13 (1): 3-11
36. Frawley PJ, Smith JW. Chemical aversion therapy in the treatment of cocaine dependence as part of a multimodal treatment program: treatment outcome. J Subst Abuse Treat 1990; 7: 219
37. Smith MO. Acupuncture treatment for crack: clinical survey of 1500 patients treated. Am J Acupuncture 1988; 16: 241-7
38. Margolin A, Avants SK, Chang C, et al. Acupuncture for the treatment of cocaine dependence in methadone-maintained patients. Am J Addict 1993; 2(3): 194-201
39. Avants SK, Margolin A, Chang P, et al. Acupuncture for the treatment of cocaine addiction: investigation of a needle puncture control. J Subst Abuse Treat 1995; 12 (3): 195-205
40. Johnson DN, Vocci FJ. Medications development at the National Institute on Drug Abuse: cocaine. NIDA Res Monogr 1993; 135: 57-70
41. Landry DW. Immunotherapy for cocaine addiction. Sci Am 1997 Feb; 276 (2): 42-5
42. Kosten TR, Morgan CM, Falcione J, et al. Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Arch Gen Psychiatry 1992; 49: 894-8
43. Handelsman L, Limpitlaw L, Williams D, et al. Amantadine does not reduce cocaine use or craving in cocaine-dependent methadone maintenance patients. Drug Alcohol Depend 1995; 39 (3): 173-80
44. Kampman K, Volpicelli JR, Alterman A, et al. Amantadine in the early treatment of cocaine dependence, a double-blind, placebo-controlled trial. Drug Alcohol Depend 1996; 41 (1): 25-33
45. Alterman AI, Droba M, Antelo RE, et al. Amantadine may facilitate detoxification of cocaine addicts. Drug Alcohol Depend 1992; 31 (1): 19-29
46. Margolin A, Kosten TR, Avants SK, et al. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend 1995; 40: 125-31
47. Giannini AJ, Baumgartel P, DiMarzio LR. Bromocriptine therapy in cocaine withdrawal. J Clin Pharmacol 1987; 27: 267-70
48. Preston KL, Sullivan JT, Strain EC, et al. Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers. J Pharmacol Exp Ther 1992; 292: 279-91
49. Moscovitz H, Brookoff D, Nelson L. A randomised trial of bromocriptine for cocaine users presenting to the emergency department. J Gen Intern Med 1993; 8: 1-4
50. Handelsman L, Rosenblum A, Palij M, et al. Bromocriptine for cocaine dependence: a controlled clinical trial. Am J Addict 1997; 6 (1): 54-64
51. Oliveto AH, Kosten TR, Schottenfeld R, et al. Cocaine use in buprenorphine vs methadone-maintained patients. Am J Addict 1994; 3 (1): 43-8
52. Hatsukami D, Keenan R, Halikas J, et al. Effects of carbamazepine on acute responses to smoked cocaine-base in human cocaine users. Psychopharmacology, 1991; 104: 120-4
53. Cornish JW, Maany I, Fudala PJ, et al. Carbamazepine treatment for cocaine dependence [abstract]. 147th Annual Meeting of the American Psychiatric Association. 1994 May 21-6; Philadelphia
54. Gawin FH, Kleber H, Byck R, et al. Desipramine facilitation of initial cocaine abstinence. Arch Gen Psychiatry 1989; 46: 117-21
55. Levin FR, Lehman AF. Meta-analysis of desipramine as an adjunct in the treatment of cocaine addiction. J Clin Pharmacol 1991; 11 (6): 374-8
56. Arndt IO, Dorozynsky L, Woody GE, et al. Desipramine treatment of cocaine dependence in methadone-maintained patients. Arch Gen Psychiatry 1992; 49 (11): 888-93
57. Carrol KM, Rounsaville BJ, Gordon LT, et al. Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Arch Gen Psychiatry 1994; 51: 177-87
58. Hall SM, Tunis S, Triffleman E, et al. Continuity of care and desipramine in primary cocaine abusers. J Nerv Ment Dis 1994; 182 (10): 570-5
59. Batki SL, Washburn AM, Delucchi K, et al. A controlled trial of fluoxetine in crack cocaine dependence. Drug Alcohol Depend 1996; 41: 137-42
60. Grabowski J, Rhoades H, Elk R, et al. Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled, double-blind trials. J Clin Pharmacol 1995; 15 (3): 163-74
61. Covi L, Hess JM, Kreiter NA, et al. Effects of combined fluoxetine and counseling in the outpatient treatment of cocaine abusers. Am J Drug Alcohol Abuse 1995; 21 (3): 327-44
62. Galloway GP, Newmeyer J, Knapp T, et al. Imipramine for the treatment of cocaine and methamphetamine dependence. J Addict Dis 1994; 13 (4): 201-16
63. Nunes EV, McGrath PJ, Quitkin FM, et al. Imipramine treatment of cocaine abuse: possible boundaries of efficacy. Drug Alcohol Depend 1995; 39 (3): 185-95
64. Wolfsohn R, Angrist B. A pilot trial of levedopa/carbidopa in early cocaine abstinence. J Clin Psychopharmacol 1990; 10 (6): 440-2
65. Chadwick MJ, Gregory DL, Wendling G. A double-blind amino acids. L-trytophan and L-tyrosine, and placebo study with cocaine-dependent subjects in an inpatient chemical dependency treatment center. Am J Drug Abuse 1990; 16 (3-4): 275-86
66. Kosten TR, Steinberg M. Diakogiannis IA. Crossover trial of mazindol for cocaine dependence. Am J Addict 1993; 2 (2): 161-4
67. Preston KL, Sullivan JT, Berger P. Effects of cocaine alone and in combination with mazindol in human cocaine users. J Pharmacol Exp Ther 1993; 267: 296-307
68. Margolin A, Avants SK, Kosten TR. Mazindol for relapse prevention to cocaine abuse in methadone-maintained patients. Am J Drug Alcohol Abuse 1995; 21 (4): 469-81
69. Stine SM, Krystal JH, Kosten TR, et al. Mazindol treatment for cocaine dependence. Drug Alcohol Depend 1995; 39 (3): 245-52
70. Wiseman EJ, McMillan DE. Transdermal nicotine and drug craving. Am J Addict 1995; 4 (3): 261-6
71. Muntamer C, Kumor KM, Nagoshi C, et al. Effects of nifedipine pretreatment on subjective and cardiovascular responses to intravenous cocaine in humans. Psychopharmacology 1991; 105 (1): 37-51
72. Crosby RD, Pearson VL, Eller C, et al. Phenytoin in the treatment of cocaine abuse: a double-blind study. Clin Pharmacol Ther 1996; 59 (4): 458-68
73. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd ed. rev. Washington, DC: American Psychiatric Association, 1987
74. Kosten TR, Schumann B, Wright D. et al. A preliminary study of desipramine in the treatment of cocaine abuse in methadone maintenance patients. J Clin Psychiatry 1987; 48 (11): 442-4
75. Fischman MW, Foltin RW, Nestadt G, et al. Effects of desipramine maintenance on cocaine self-administration by humans. J Pharmacol Exp Ther 1990; 253 (2): 760-70
76. Foltin RW, Fischman MW, Levin FR. Cardiovascular effects of cocaine in humans: laboratory studies. Drug Alcohol Depend 1995; 37 (3): 193-210
77. Nunes EV, Quitkin FM, Brady R, et al. Imipramine treatment of methadone maintenance patients with affective disorder and illicit drug use. Am J Psychiatry 1991; 148 (5): 667-9
78. Batki SL, Manfredi LB, Jacob P, et al. Fluoxetine for cocaine dependence in methadone maintenance: quantitative plasma and urine cocaine/benzoylecgonine concentrations. J Clin Psychopharmacol 1993; 13 (4): 243-50
79. Batki SL, Washburn A, Manfredi LB, et al. Fuoxetine in primary and secondary cocaine dependence: outcome measured by quantitative benzoylecgonine concentration [abstract]. NIDA Res Monog; 141: 140, National Institute on Drug Abuse, NIH Public. No. 94-3749. Rockville (MD): US Department of Health and Human Services, 1994
80. Walsh SL, Preston KL, Sullivan JT, et al. Fluoxetine alters the effects of intravenous cocaine in humans. J Clin Psychopharmacol 1994; 14 (6): 396-407
81. Hollister LE, Krajewski K, Rustin T, et al. Drugs for cocaine dependence: not easy [letter]. Arch Gen Psychiatry 1992; 49: 905
82. Montoya ID, Preston KL, Cone EJ, et al. Safety and efficacy of bupropion combined with bromocriptine for treatment of cocaine dependence. Am J Addict 1996 5 (1): 69-79
83. Halikas JA, Kuhn KL, Maddux TL. Reduction of cocaine use among methadone maintenance patients using concurrent carbamazepine. Ann Clin Psychiatry 1990: 2: 3-6
84. Berger P, Gawin E, Kosten TR. Treatmenl of cocaine abuse with mazindol [letter]. Lancet 1989 Feb; 1: 283
85. Khantzian EJ, Gawin FH, Kleber HD, et al. Methylphenidate treatment of cocaine dependence a preliminary report. J Subst Abuse Treat 1984: 1: 107-12
86. Kosten TR, Kleber HD, Morgan CH. Treatment of cocaine abuse with buprenorphine. Biol Psychiatry 1989; 26: 637-9
87. Kosten TR, Kleber HD, Morgan C. Role of opioid antagonists in treating intravenous cocaine abuse. Life Sci 1989; 44: 887-92
88. Wolfsohn R, Sanfilipo M, Angrist B. A placebo-controlled trial of L-dopa/carbidopa in early cocaine abstinence. Neuropsychopharmacology 1993; 9: 49-53
89. Higgins ST, Budney AJ, Bickel WK, et al. Disulfiram therapy in patients abusing cocaine and alcohol. Am J Psychiatry 1993; 150 (4): 675-6
90. Carroll KM, Ziedonis D, O'Malley SS, et al. Pharmacological interventions for abusers of alcohol and cocaine: disulfiram versus naltrexone. Am J Addict 1993; 2: 77-9
91. Gawin FH, Khalsa Denison EM, Jatlow P. Flupenthixol-induced aversion to crack cocaine. N Engl J Med 1996; 334 (20): 1340-1
92. Gawin FH, Allen D, Humblestone B. Outpatient treatment of 'crack' cocaine smoking with flupenthixol decanoate. Arch Gen Psychiatry 1989; 46: 322-5
93. Khouzam HR, Mayo-Smith MF, Bernard DR, et al. Treatment of crack-cocaine-induced compulsive behavior with trazodone. J Subst Abuse Treat 1995; 12 (2): 85-8
94. Kosten TA, Kosten TR, Gawin FH. An open trial of sertraline for cocaine abuse. Am J Addict 1992; 1 (4): 349-53
95. Goldwyn DH. Cocaine abuse treated with phenelzine. Int J Addict 1988; 23 (9): 897-905
96. Margolin A, Avants SK, Falcioni J, et al. Preliminary investigation of selegiline for the treatment of cocaine dependence. Am J Addict 1996; 15 (3): 275-6
97. Margolin A, Avants SK, Kosten TR. Pemoline for the treatment of cocaine dependence in methadone-maintained patients. J Psychoactive Drugs 1996; 28 (3): 301-4